BioSpace News Archive

Merck’s checkpoint inhibitor Keytruda (pembrolizumab) proved itself effective in yet another cancer indication.

As Sanofi continues to undergo a planned renovation announced in December, it will do so without four long-time executives.

Bayer is moving closer to a $10 billion settlement over the Roundup lawsuits and the company is in the midst of restructuring.

While fears of a potential coronavirus or flu pandemic continue to grow across the globe, the White House is calling for a 16% cut to the budget of the U.S. Centers for Disease Control, as well as a 10% cut to the Department of Health and Human Services.

In November 2019, the U.S. Food and Drug Administration (FDA) released new draft guidance that would help generic drug companies bring biosimilars to insulin to the market more quickly. And now there are reports that two of the three primary biopharma companies that sell insulin in the U.S. are trying to change that draft guidance.

A number of new medications stand a shot at early regulatory approval thanks to the U.S. Food and Drug Administration’s priority review program.

Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.

POXEL SA announced that new preclinical proof-of-concept results for PXL770 for the treatment of NASH were reported in an oral presentation during the 3rd Annual Global NASH Congress held in London, February 10-11, 2020.

Rexgenero announces that Dr Huw Jones has joined the Company’s Board as a non-executive director, and will chair the Company’s remuneration committee.

Spark Therapeutics, Ultragenyx and Others to Headline March 24-26 Meeting in Barcelona